Leo Pharma, a Denmark dermatology company, acquired global rights to a novel treatment for atopic dermatitis (AD) and allergic asthma in an agreement worth up to $570 million. FB825 is a first-in-class candidate that targets the CεmX domain of membrane-bound IgE (mIgE), causing a depletion of mIgE positive B-cells and slowing the immune response, the company said. Leo acquired FB825 from Oneness Biotech of Taiwan and Microbio Shanghai. It made a $40 million upfront payment and will pay up to $530 million of milestones, plus royalties. More details.... Stock Symbol: (TPEx: 4743) Share this with colleagues: // //